What is the appropriate treatment for dysuria in an adult?

Treatment for Dysuria in Adults

For uncomplicated cystitis causing dysuria, start nitrofurantoin 100 mg twice daily for 5 days as first-line therapy 1.

Diagnostic Approach Before Treatment

Before initiating treatment, determine the underlying cause through:

• Urinalysis - perform in most patients with dysuria to confirm infection 2
• Urine culture - obtain for recurrent infections, suspected complicated UTI, or to guide antibiotic selection 1, 2
• Sexual history and vaginal discharge assessment - presence of vaginal discharge decreases likelihood of UTI and suggests cervicitis or sexually transmitted infection requiring different management 2

Common pitfall: Virtual encounters without laboratory testing increase recurrent symptoms and unnecessary antibiotic courses 2. Always obtain urinalysis when feasible.

Treatment Algorithm Based on Clinical Syndrome

Uncomplicated Cystitis (Lower UTI)

First-line options based on 2024 JAMA guidelines 1:

• Nitrofurantoin: 5 days (preferred - spares systemic agents, maintains low resistance)
• TMP/SMX: 3 days (if local resistance <20%)
• Fosfomycin: Single 3-gram dose
• Fluoroquinolones: 3 days (avoid as first-line due to collateral damage; reserve for when other options unavailable)

The evidence strongly supports nitrofurantoin as the optimal choice because it achieves excellent urinary concentrations, demonstrates robust efficacy, and preserves more systemically active agents for other infections 1.

Pyelonephritis (Upper UTI with Systemic Symptoms)

For outpatient management 1, 3:

• TMP/SMX or first-generation cephalosporin: 7 days (dependent on local resistance rates)
• Fluoroquinolones: 5-7 days (ciprofloxacin 7 days; levofloxacin/ofloxacin 5 days acceptable)

For patients requiring IV therapy 1, 3:

• Ceftriaxone: Preferred empirical choice (low resistance rates, excellent clinical effectiveness)
• Combination therapy: Amoxicillin + aminoglycoside OR second-generation cephalosporin + aminoglycoside for complicated cases
• Transition to oral therapy after 48 hours afebrile and hemodynamically stable

Critical caveat: Only use antipseudomonal agents (carbapenems, piperacillin-tazobactam) in patients with risk factors for nosocomial pathogens 1.

Complicated UTI

Empirical treatment requires 3:

• IV third-generation cephalosporin + aminoglycoside for systemic symptoms
• Avoid fluoroquinolones if patient is from urology department or used fluoroquinolones in last 6 months (high resistance risk)
• Only use ciprofloxacin if local resistance <10% AND patient doesn't require hospitalization
• Manage underlying urological abnormalities - this is essential, not optional

Catheter-Associated UTI

Treat according to complicated UTI recommendations 3. Duration of catheterization is the most important risk factor, with 3-8% daily incidence of bacteriuria 3.

Important distinction: Positive urinalysis in catheterized patients has very low specificity - bacteriuria is almost always present regardless of symptoms 1. Only treat symptomatic CA-UTI, not asymptomatic bacteriuria.

Urethritis (Sexually Transmitted)

If dysuria with urethral discharge or sexual exposure 3:

• Obtain nucleic acid amplification testing for gonorrhea, chlamydia
• If severe symptoms, start empirical treatment immediately
• If mild symptoms, await test results before treating
• Consider Mycoplasma genitalium testing if persistent urethritis with negative initial testing 2

Symptomatic Relief

While treating the underlying infection, consider symptomatic management:

• Methenamine 250 mg + methylthioninium chloride 20 mg demonstrated superiority over phenazopyridine for dysuria relief within 24-48 hours 4
• This combination showed 12.7% greater excellent response rate for pain relief compared to phenazopyridine

Key Clinical Pitfalls to Avoid

1. Don't treat asymptomatic bacteriuria - common in older women and catheterized patients; treatment increases resistance without benefit 1, 5

2. Don't rely solely on pyuria - commonly found without infection, especially in elderly with incontinence 5

3. Don't use fluoroquinolones as first-line - increasing resistance and significant collateral damage to microbiome 1, 5

4. Don't ignore local resistance patterns - empirical choices must account for regional antibiotic resistance rates 1

5. Don't undertake virtual treatment without urinalysis - increases treatment failures and antibiotic overuse 2